Vision restoration with photoswitch technology
Vision restoration with photoswitch technology
批准号:
7801340
负责人:
Andrew Blatz
金额:
$37.45万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-03 至 2011-07-31
关键词:
AdoptedAffectAftercareAmacrine CellsAnimal ModelAnimalsBehaviorBehavioralBlindnessCellsChildCommunitiesDataDegenerative DisorderDevelopmentDevelopment PlansDoseElectroretinographyEquipmentEvoked PotentialsExhibitsEyeEye diseasesFigs - dietaryFutureGenerationsGoalsHumanInheritedInjection of therapeutic agentIon ChannelKineticsLaboratoriesLegal patentLightMarketingMeasurementMeasuresMedicalMembrane PotentialsMethodsModelingMusNatureNeurogliaPatch-Clamp TechniquesPathway interactionsPatientsPatternPharmacologic SubstancePhasePhotophobiaPhotoreceptorsPhysiologyPropertyProsthesisProtocols documentationRare DiseasesReportingResearchResolutionRetinaRetinalRetinal ConeRetinal DegenerationRetinitis PigmentosaRightsSafetySchoolsSmall Business Innovation Research GrantStimulusTechnologyTestingTherapeuticTimeVertebrate PhotoreceptorsVisionVisualZebrafishassay developmentblindcell typedrug candidateextracellularganglion cellgene therapyhorizontal cellimprovedin vivoinstrumentmeetingsmouse modelmutantpre-clinicalpublic health relevanceresponserestorationsmall moleculesuccesstheoriestherapeutic developmenttherapeutic target
中文摘要
描述(由申请人提供):视网膜色素变性(RP)是一种遗传性疾病的眼睛,剥夺其受害者的视力。视力的丧失是由视网膜的视杆细胞和视锥细胞的变性引起的,而视网膜中的其他细胞仍然存活。RD是一种相对罕见的疾病,在美国约有10万人受到影响。盲校中约有20%的儿童患有RP。显然,RP的灾难性后果为深入研究其原因和潜在的治疗方法提供了理由。由于RP的多基因性质,它不适合基因治疗或靶向治疗。虽然已经报道了使用基因疗法在视力恢复方面的一些成功,但这种疗法在不久的将来被医学界批准和采用的可能性很小。在第一阶段SBIR应用中提出了一种不涉及基因治疗的RP患者视力恢复的替代方法,其中使用称为“光开关”的小分子将受损视网膜中的剩余细胞制成光敏细胞。从理论上讲,光开关可以提供比竞争对手的视频摄像机假肢高出大约一千倍的分辨率,并且侵入性要小得多。沿着获得批准的治疗剂的途径的前几步的四个具体目标是(1)通过将光开关注射到盲小鼠的眼睛中来确定视网膜中的许多细胞中的哪些细胞被赋予光敏性;(2)使用非侵入性电生理学方法来证明完整突变盲小鼠的光敏性;(3)证明光开关治疗后遗传盲小鼠的光依赖行为;和(4)确定维持突变盲小鼠光敏感性的最佳参数。该可行性项目的成功完成将为进一步追求这种治疗失明的方法提供理由。
公共卫生相关性:视网膜色素变性(RP)是一种遗传性眼病,剥夺其受害者的视力。虽然RD是一种相对罕见的疾病,在美国影响约10万人,但约20%的盲校儿童患有RP。显然,RP的灾难性后果为深入研究其原因和潜在的治疗方法提供了理由。Photoswitch Biosciences开发了一种技术,该技术有可能使眼睛中的健康细胞变成可以接收和解码光线的细胞,从而恢复RP患者的视力。
英文摘要
DESCRIPTION (provided by applicant): Retinitis Pigmentosa (RP) is an inherited disease of the eye that robs its victims of vision. The loss of vision is caused by the degeneration of the rods and cones of the retina while other cells in the retina remain alive. RD is a relatively rare disease, affecting approximately 100,000 people in the US. Approximately 20% of children in schools for the blind suffer from RP. Clearly, the disastrous consequences of RP provide justification for intense research into the causes and potential therapies. Due to the polygenic nature of RP, it does not lend itself to gene therapy or targeted therapeutics. Although some successes in vision restoration using gene therapy have been reported, it is highly unlikely that such therapy will be approved and adopted by the medical community in the near future. An alternative approach to vision restoration for patients with RP, which does not involve gene therapy, is proposed in this Phase I SBIR application where the remaining cells in the damaged retina are made into photosensitive cells using small molecules called "photoswitches". Photoswitches could, in theory, provide resolution approximately a thousand times greater than that of competing video camera prosthetics and will be far less invasive. The four Specific Aims for the first steps along the pathway to an approved therapeutic are (1) Determine which of the many cells in the retina are rendered light-sensitive by the injection of photoswitches into the eyes of blind mice; (2) Demonstrate light-sensitivity in intact mutant blind mice using non-invasive electrophysiological approaches; (3) Demonstrate light-dependent behavior in genetically blind mice after photoswitch treatment; and (4) Determine the optimal parameters for maintaining light-sensitivity in mutant blind mice. The successful completion of this feasibility project will provide justification for the further pursuit of this therapeutic approach to blindness.
PUBLIC HEALTH RELEVANCE: Retinitis Pigmentosa (RP) is an inherited disease of the eye that robs its victims of vision. While RD is a relatively rare disease, affecting approximately 100,000 people in the US, approximately 20% of children in schools for the blind suffer from RP. Clearly, the disastrous consequences of RP provide justification for intense research into the causes and potential therapies. Photoswitch Biosciences has developed a technology that has the potential to make healthy cells in the eye into cells that can receive and decode light, restoring sight to sufferers of RP.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ion Channel Screening Using Photoswitches
-
批准号:8646676
-
项目类别:
-
资助金额:$19.33万
-
财政年份:2014
-
负责人:Andrew Blatz
-
依托单位:
Ion Channel Screening Using Photoswitches
-
批准号:8887728
-
项目类别:
-
资助金额:$59.62万
-
财政年份:2014
-
负责人:Andrew Blatz
-
依托单位:
Ion Channel Drug Discovery Using Photoswitch Technology
-
批准号:8251668
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2010
-
负责人:Andrew Blatz
-
依托单位:
Ion Channel Drug Discovery Using Photoswitch Technology
-
批准号:8417658
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2010
-
负责人:Andrew Blatz
-
依托单位:
Ion Channel Drug Discovery Using Photoswitch Technology
-
批准号:7801106
-
项目类别:
-
资助金额:$33.49万
-
财政年份:2010
-
负责人:Andrew Blatz
-
依托单位:
海外基金